Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of giant cell arteritis (GCA) according to the following criteria:~  * History of erythrocyte sedimentation rate (ESR) \>= 50 mm/hour or high sensitivity C-reactive protein (hsCRP)/CRP \>=1.0 mg/dL~ * Presence of at least one of the following: Unequivocal cranial symptoms of GCA or Unequivocal symptoms of polymyalgia rheumatica (PMR)~ * Presence of at least one of the following: temporal artery biopsy revealing features of GCA or evidence of large vessel vasculitis by angiography or cross-sectional imaging such as ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) or positron emission tomography (PET).~* Active GCA, either new onset or relapsing, within 8 weeks of Baseline.~* Participants must have received treatment with \>=40 mg prednisone (or equivalent) at any time prior to Baseline and be receiving prednisone (or equivalent) \>= 20 mg once daily (QD) at Baseline.~* Participants must have GCA that, in the opinion of the investigator, is clinically stable to allow the participant to safely initiate the protocol-defined corticosteroid (CS) taper regimen.~* Females must either be postmenopausal or permanently surgically sterile or, practicing at least 1 specified method of birth control through the study.~Exclusion Criteria:~* Prior exposure to any Janus Kinase (JAK) inhibitor.~* Treatment with an interleukin-6 (IL-6) inhibitor within 4 weeks of study start, or prior treatment with an IL-6 inhibitor and experienced a disease flare during treatment.~* Use of any of the following systemic immunosuppressant treatments within the specified timeframe prior to study start:~  * Anakinra within 1 week of study start.~ * Methotrexate, hydroxychloroquine, cyclosporine, azathioprine, or mycophenolate within 4 weeks of study start.~ * Oral corticosteroid (CS) for conditions other than GCA within 4 week of study start, or intravenous CS within 4 weeks of study start.~ * Greater than or equal to 8 weeks for leflunomide if no elimination procedure was followed, or adhere to an elimination procedure.~ * Cell-depleting agents or alkylating agents including cyclophosphamide within 6 months of study start.~* Current or past history of infection including herpes zoster or herpes simplex, human immunodeficiency virus (HIV), active Tuberculosis, active or chronic recurring infection, active hepatitis B or C.~* Female who is pregnant, breastfeeding, or considering pregnancy during the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Upadacitinib dose A administered daily + 26-week CS taper regimen
- Arm B (Type: EXPERIMENTAL): Upadacitinib dose B administered daily + 26-week CS taper regimen
- Arm C (Type: PLACEBO_COMPARATOR): Placebo administered daily + 52-week CS taper regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).